Results 11 to 20 of about 111,297 (312)

Design and Evaluation of Dissolving Microneedles for Enhanced Dermal Delivery of Propranolol Hydrochloride

Pharmaceutics, 2021
Oral propranolol hydrochloride has been the first-line treatment for infantile hemangioma (IH), whereas systemic exposure to propranolol has the potential of causing serious adverse reactions.
Jingjing He, Zichen Zhang, Xianzi Zheng, Lu Li, Jianping Qi, Wei Wu, Yi Lu   +6 more
doaj   +2 more sources

Involvement of propranolol in suicides: cross-sectional study using coroner-reported data [PDF]

BJPsych Open
Background Propranolol is a beta-blocker medication indicated mostly for heart rhythm conditions and for physical symptoms of anxiety. Prescriptions for propranolol in the UK have increased since 2008.
Hayley C. Gorton, Charlotte Archer, Thikra Algahtani, Faraz Mughal, Caroline S. Copeland   +4 more
doaj   +3 more sources

Propranolol: A 50-year historical perspective

Annals of Indian Academy of Neurology, 2019
Propranolol is a beta-adrenergic receptor antagonist that was developed by the British scientist Sir James Black primarily for the treatment of angina pectoris, more than 50 years ago.
A V Srinivasan
doaj   +2 more sources

Facile Synthesis of Propranolol and Novel Derivatives

Journal of Chemistry, 2020
Propranolol is one of the first medications of the beta-blocker used for antihypertensive drugs. This study reports the facile route for the synthesis of propranolol and its novel derivatives.
Vy Anh Tran, Nguyen Hai Tai Tran, Long Giang Bach, Trinh Duy Nguyen, Thi Thuong Nguyen, Tan Tai Nguyen, Thi Anh Nga Nguyen, The Ky Vo, Thu-Thao Thi Vo, Van Thuan Le   +9 more
doaj   +2 more sources

Propranolol 0.2% Eye Micro-Drops for Retinopathy of Prematurity: A Prospective Phase IIB Study

Frontiers in Pediatrics, 2019
Background: Oral propranolol reduces retinopathy of prematurity (ROP) progression, although not safely. Propranolol 0.1% eye micro-drops administered to newborns with stage 2 ROP are well-tolerated, but not sufficiently effective.Methods: A multi-center ...
Luca Filippi, Giacomo Cavallaro, Giacomo Cavallaro, Elettra Berti, Letizia Padrini, Gabriella Araimo, Giulia Regiroli, Giulia Regiroli, Genny Raffaeli, Genny Raffaeli, Valentina Bozzetti, Paolo Tagliabue, Barbara Tomasini, Annalisa Mori, Giuseppe Buonocore, Massimo Agosti, Angela Bossi, Gaetano Chirico, Salvatore Aversa, Pina Fortunato, Silvia Osnaghi, Barbara Cavallotti, Martina Suzani, Maurizio Vanni, Giulia Borsari, Simone Donati, Giuseppe Nascimbeni, Daniel Nardo, Stefano Piermarocchi, Giancarlo la Marca, Giulia Forni, Silvano Milani, Ivan Cortinovis, Maura Calvani, Paola Bagnoli, Massimo Dal Monte, Anna Maria Calvani, Alessandra Pugi, Eduardo Villamor, Gianpaolo Donzelli, Fabio Mosca, Fabio Mosca   +41 more
doaj   +2 more sources

Propranolol therapy for infantile hemangioma: our experience

Drug Design, Development and Therapy, 2017
Objective Hemangiomas are the most common benign vascular tumors of infancy. Although most infantile hemangiomas (IHs) have the ability to involute spontaneously after initial proliferation and resolve without consequence, intervention is required in a ...
Ling Zhang, H. Wu, Wei-En Yuan, Jia-wei Zheng   +3 more
semanticscholar   +2 more sources

Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression

Scientific Reports, 2018
Propranolol, a widely used non-selective beta-adrenergic receptor blocker, was recently shown to display anticancer properties. Its potential to synergize with certain drugs has been also outlined.
Laura Brohée, Olivier Peulen, Betty Nusgens, Vincent Castronovo, Marc Thiry, Alain C. Colige, Christophe F. Deroanne   +6 more
doaj   +2 more sources

When to stop propranolol for infantile hemangioma

Scientific Reports, 2017
There is no definitive conclusion regarding the optimal timing for terminating propranolol treatment for infantile hemangioma (IH). A total of 149 patients who underwent detailed color Doppler ultrasound examination were included in this study.
Lei Chang, Yifei Gu, Zhang Yu, Hanru Ying, Y. Qiu, G. Ma, Hui Chen, Yunbo Jin, Xiaoxi Lin   +8 more
semanticscholar   +2 more sources

Evaluating Neurodevelopmental Sequelae of Propranolol Use in Infantile Hemangioma: A Large‐Scale Population‐Based Study

JEADV Clinical Practice
Background Propranolol is widely adopted as the first‐line treatment for problematic infantile hemangioma (IH). Despite its efficacy and widespread use, concerns persist about potential long‐term neurodevelopmental risks, given propranolol′s ability to ...
Khalaf Kridin, Samer Kridin, Wisal Sawaed, Ralf J. Ludwig   +3 more
doaj   +2 more sources

Plasma Drug Concentration of Propranolol and Genetic Study in Chinese Han Patients With Infantile Haemangioma

Frontiers in Pediatrics, 2022
Background and PurposeThis study was conducted to explore the plasma drug concentration of propranolol in Chinese Han patients with infantile haemangioma (IH) and the influencing factors, as well as the relationship among plasma drug concentrations of ...
Li Li, Lu Yu, Huan He, Li Wei, Zigang Xu, Libo Zhao, Yujuan Sun, Bin Zhang, Yuanxiang Liu, Rui He, Xiaoling Wang, Lin Ma   +11 more
doaj   +1 more source